Skip to content

Analysis of Risk Factors for Cognitive Frailty in Stroke Patients and the Mechanism of Lipid Metabolism Reprogramming in Hyperbaric Oxygen Therapy

Analysis of Risk Factors for Cognitive Frailty in Stroke Patients and the Mechanism of Lipid Metabolism Reprogramming in Hyperbaric Oxygen Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125734
Enrollment
Unknown
Registered
2026-05-29
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive frailty

Interventions

Post-stroke cognitive impairment control group:Medication and conventional rehabilitation therapy (muscle strength training, range of motion training, gait training, balance function training, cogniti
Post-stroke cognitive impairment hyperbaric oxygen therapy group:Medication and conventional rehabilitation therapy (muscle strength training, range of motion training, gait training, balance function

Sponsors

Shanghai Pudong New Area People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age between 40 and 75 years; 2. Stroke patients with cognitive impairment, MoCA score < 26; 3. First-ever hemorrhagic or ischemic stroke confirmed by neuroimaging; 4. The patient is conscious and has stable vital signs; 5. The patient or their legal guardian agrees and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals with transient ischemic attacks with reversible neurological deficits or multiple strokes with other secondary changes. 2. Individuals with multiple cerebral hemorrhagic lesions. 3. Individuals with stroke combined with primary diseases of the hematopoietic system, liver and kidney systems, or endocrine system. 4. Individuals with hydrocephalus, recurrent strokes, or other neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis). 5. Individuals with a history of seizures, undergoing thrombolytic therapy, chronic obstructive pulmonary disease with CO2 retention, pneumothorax, intestinal obstruction, sickle cell disease, arrhythmia, claustrophobia, blood pressure >180/120 mmHg, or other heart diseases combined with atrial fibrillation.

Design outcomes

Primary

MeasureTime frame
Cognitive function assessment;Stroke Recurrence Risk Assessment;Imaging Assessment of Cognitive Function;Blood-Based Biochemical Marker Testing for Cognitive Function;Lipidomics Analysis;

Secondary

MeasureTime frame
General Data Collection and Examination;Blood Glucose and Lipid Profile (Four Items);

Countries

China

Contacts

Public ContactJingyun Hu

Shanghai Pudong New Area People’s Hospital

jingyunhu121@126.com+86 188 1735 0142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026